22 results
424B3
IKT
Inhibikase Therapeutics Inc
4 Apr 23
Prospectus supplement
4:57pm
, and similar anti-bribery and anti-corruption laws.
Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws
POS AM
IKT
Inhibikase Therapeutics Inc
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
Practices Act, or FCPA, and similar anti-bribery and anti-corruption laws.
Our business activities may be subject to the FCPA and similar anti-bribery … or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits
424B4
2mtesb97guhs1
17 Jun 21
Prospectus supplement with pricing info
4:31pm
8-K
EX-1.1
w3kuhr
16 Jun 21
Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock
9:20am
DRS
zuee5h1b
2 Jun 21
Draft registration statement
12:00am
DRS
EX-1.1
zujpl
2 Jun 21
Draft registration statement
12:00am
10-K
2xkc zz0u
31 Mar 21
Annual report
2:14pm
424B4
tt50ejmo
28 Dec 20
Prospectus supplement with pricing info
6:04am
S-1
g7jyidfzv1 5x9
23 Jul 20
IPO registration
12:28pm